Communications Biology (Apr 2022)
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
- Gaia Bianco,
- Mairene Coto-Llerena,
- John Gallon,
- Venkatesh Kancherla,
- Stephanie Taha-Mehlitz,
- Mattia Marinucci,
- Martina Konantz,
- Sumana Srivatsa,
- Hesam Montazeri,
- Federica Panebianco,
- Vijaya G. Tirunagaru,
- Marta De Menna,
- Viola Paradiso,
- Caner Ercan,
- Ahmed Dahmani,
- Elodie Montaudon,
- Niko Beerenwinkel,
- Marianna Kruithof-de Julio,
- Luigi M. Terracciano,
- Claudia Lengerke,
- Rinath M. Jeselsohn,
- Robert C. Doebele,
- François-Clément Bidard,
- Elisabetta Marangoni,
- Charlotte K. Y. Ng,
- Salvatore Piscuoglio
Affiliations
- Gaia Bianco
- Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel
- Mairene Coto-Llerena
- Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel
- John Gallon
- Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel
- Venkatesh Kancherla
- Institute of Medical Genetics and Pathology, University Hospital Basel
- Stephanie Taha-Mehlitz
- Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel
- Mattia Marinucci
- Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel
- Martina Konantz
- Department of Biomedicine, University of Basel and University Hospital Basel
- Sumana Srivatsa
- Department of Biosystems Science and Engineering, ETH Zurich
- Hesam Montazeri
- Institute of Medical Genetics and Pathology, University Hospital Basel
- Federica Panebianco
- Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel
- Vijaya G. Tirunagaru
- Rain Therapeutics Inc
- Marta De Menna
- Department of Biomedical Research, Urology Group, University of Bern
- Viola Paradiso
- Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel
- Caner Ercan
- Institute of Medical Genetics and Pathology, University Hospital Basel
- Ahmed Dahmani
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center
- Elodie Montaudon
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center
- Niko Beerenwinkel
- Department of Biosystems Science and Engineering, ETH Zurich
- Marianna Kruithof-de Julio
- Rain Therapeutics Inc
- Luigi M. Terracciano
- Institute of Medical Genetics and Pathology, University Hospital Basel
- Claudia Lengerke
- Department of Biomedicine, University of Basel and University Hospital Basel
- Rinath M. Jeselsohn
- Division of Women’s Cancers, Dana-Farber Cancer Institute, Harvard Medical School
- Robert C. Doebele
- Rain Therapeutics Inc
- François-Clément Bidard
- Department of Medical Oncology, Institut Curie
- Elisabetta Marangoni
- Department of Biomedical Research, Urology Group, University of Bern
- Charlotte K. Y. Ng
- Institute of Medical Genetics and Pathology, University Hospital Basel
- Salvatore Piscuoglio
- Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel
- DOI
- https://doi.org/10.1038/s42003-022-03296-x
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 15
Abstract
GATA3 mutations are common in ER-positive breast cancers yet are not targetable. This study describes pharmacological inhibition of MDM2 as a novel approach to target GATA3 deficiency, providing a molecularly guided treatment for this patient subclass associated with a worse prognosis and relapse.
